Alternatively, in recent years, imaging studies using radiolabeled EGFR TKI have shown that PET could potentially be of value for identifying EGFR mutation positive patients and predicting tumor sensitivity to EGFR TKI (27–31). The gene discussed is EGFR; the disease is neoplasm.